AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-MEDICAL LABORATORIES
Veracyte, Inc.
XNAS · usd
SIC 8071 · SERVICES-MEDICAL LABORATORIES
FIGI BBG001TSQWW0
47.93▲ 1.89 (4.11%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
46.04
Day's Range
45.48 – 48.07
52-Week Range
29.45 – 60.91
Volume
906.0K
Avg Volume
1.4M
Share Statistics
Shares Outstanding
Employees
755
Exchange
XNAS
Listed
2013-10-30
Share count as of July 27, 2026

Veracyte, Inc. (VCYT) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Veracyte, Inc. (VCYT)
What is Veracyte, Inc.'s Market Cap?
Veracyte, Inc.'s Market Cap is $3.9B, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Trailing P/E?
Veracyte, Inc.'s Trailing P/E is 33.7×, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Price / Sales?
Veracyte, Inc.'s Price / Sales is 6.9×, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Revenue (TTM)?
Veracyte, Inc.'s Revenue (TTM) is $561.9M, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Net Income (TTM)?
Veracyte, Inc.'s Net Income (TTM) is $114.5M, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s EBITDA?
Veracyte, Inc.'s EBITDA is $126.6M, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Diluted EPS (TTM)?
Veracyte, Inc.'s Diluted EPS (TTM) is 1.42, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s EBITDA Margin?
Veracyte, Inc.'s EBITDA Margin is 22.5%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · VCYTAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth+15.5%+21.5%+18.5%+13.8%
Cost of revenue:
Cost of revenue————
Intangible asset amortization - cost of revenue
Total cost of revenue
Gross profit
% of revenue72.2%72.7%72.5%69.2%
Operating expenses:
Research and development
Selling and marketing
General and administrative
Impairment loss—
Intangible asset amortization - operating expenses
Total operating expenses
% of revenue56.9%56.5%46.1%51.8%
Income (loss) from operations
% of revenue15.3%16.3%26.4%17.4%
Other income, net
Income before income taxes
Income tax provision
Net income (loss)
% of revenue17.0%20.6%29.3%14.5%
Basic (in USD per share)
Diluted (in USD per share)